UCB SA (OTCMKTS:UCBJY) Short Interest Down 80.0% in December

UCB SA (OTCMKTS:UCBJY) was the recipient of a significant decline in short interest in December. As of December 15th, there was short interest totalling 200 shares, a decline of 80.0% from the November 30th total of 1,000 shares. Based on an average daily trading volume, of 11,900 shares, the short-interest ratio is presently 0.0 days.

UCB Price Performance

OTCMKTS:UCBJY traded up $0.22 during trading hours on Friday, hitting $99.24. The stock had a trading volume of 5,171 shares, compared to its average volume of 17,404. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The business has a 50 day simple moving average of $95.93 and a two-hundred day simple moving average of $88.20. UCB has a 1-year low of $43.17 and a 1-year high of $100.01.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.